VenomAid Diagnostics
VenomAid Diagnostics is a Danish medtech startup developing affordable, rapid lateral flow assay-based diagnostic tests that detect snake venom in patient samples at the point of care, serving healthcare systems and clinicians in resource-limited tropical regions, with initial market focus on Brazil and Latin America.
- Company typePrivate
- Founded2018
- HeadquartersKongens Lyngby, Denmark
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What VenomAid Diagnostics does
VenomAid Diagnostics ApS is a Danish medtech startup founded in 2018 and headquartered in Kongens Lyngby, Denmark, that develops affordable rapid in vitro diagnostic tests for snakebite envenoming. The company applies proprietary monoclonal antibody and nanobody technologies combined with venomics insights to build lateral flow assay-based kits that detect snake venom in patient blood, plasma, urine, or sera at the point of care. Its flagship product, the Bothrops Kit, identifies Bothrops genus venom (accounting for 70–80% of South American snakebites) within 15 minutes, with a limit of detection of 10–50 ng/mL in spiked plasma and urine. The company also publishes a multiplex assay (distinguishing Bothrops and Lachesis venoms) and is developing a paper-based nanobody diagnostic platform.
The company's customers are healthcare systems, hospitals, clinics, and clinical personnel in tropical, resource-limited regions — particularly Brazil and Latin America — who currently lack rapid tools to identify envenoming species and select appropriate antivenoms. VenomAid's go-to-market is product-led, deploying low-cost, portable, easy-to-use kits directly into clinical settings, with clinical pilots planned in Brazil and contract manufacturing established via a partnership with Abingdon Health. Revenue mechanics are not yet disclosed as the company is pre-commercial; its funding to date totals approximately $1.8 million in seed equity from Good Ventures LLC and private Business Angels, supplemented by grants from the Novo Nordisk Foundation (Pioneer Innovator) and Innovation Fund Denmark (Innobooster and Industrial PhD). Core operating geographies are Denmark (R&D and headquarters) and Brazil (initial commercial market).
VenomAid Diagnostics firmographics
Firmographics- Name
- VenomAid Diagnostics
- Legal name
- VenomAid Diagnostics ApS
- Website
- https://venomaid.com
- Company type
- Private
- Founded year
- 2018
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- VenomAid Diagnostics is a Danish medtech startup developing affordable, rapid lateral flow assay-based diagnostic tests that detect snake venom in patient samples at the point of care, serving healthcare systems and clinicians in resource-limited tropical regions, with initial market focus on Brazil and Latin America.
- Ownership category
- akta.pro rank
VenomAid Diagnostics industry classification
Industry- Product category
- In Vitro Diagnostics
- NAICS
- In-Vitro Diagnostic Substance Manufacturing (325413)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835)
- akta.pro primary industry
- Drug-of-Abuse & Toxicology Rapid Tests (Urine/saliva panels) (HLAHAOAG)
- akta.pro secondary industry
- Immunoassay Diagnostics (ELISA, chemiluminescence, serology) (HLAAALAB)
Keywords
Where VenomAid Diagnostics is headquartered
LocationHeadquarters
- HQ city
- Kongens Lyngby
- HQ country
- Denmark
- HQ region
- Europe
Offices1 record
Markets served
VenomAid Diagnostics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Supply Chain, Infrastructure, Marketing or Sales
Revenue model
- Bothrops Kit Sales: Sale of the Bothrops rapid diagnostic kit for detecting envenomings from Lancehead snakes (Bothrops genus) in Brazil and Latin American markets to guide antivenom selection.
Go-to-market motion1 record
Distribution channels2 records
Marketing channels7 records
VenomAid Diagnostics product offering
Product offeringCore offering
VenomAid Diagnostics develops affordable, rapid in vitro diagnostic tests for snakebite envenoming using proprietary monoclonal antibody and nanobody-based lateral flow assay technology. The flagship Bothrops Kit uses a small patient blood sample to detect Bothrops genus snake venom at point of care within 15 minutes, enabling healthcare workers in resource-limited settings to quickly identify venom type and select appropriate antivenom treatment.
Product overview
VenomAid Diagnostics offers a portfolio of lateral flow assay-based diagnostic products for snakebite envenoming detection. The flagship product is the Bothrops Kit, an affordable rapid in vitro diagnostic that detects Bothrops genus snake venom from patient blood samples at point of care. The Multiplex Lateral Flow Assay extends this capability to simultaneously detect Bothrops and Lachesis venoms with smartphone-assisted quantitative readouts. The company is also developing a nanobody-based paper diagnostic platform for broader toxin detection. All products are designed for resource-limited settings and aim to enable rapid, accurate snakebite diagnosis to guide appropriate antivenom selection.
Differentiator
Problem solved
Functional benefit
Products and services
- Bothrops Kit Affordable, rapid in vitro diagnostic test for management of snakebite that uses a small blood sample to identify Bothrops genus venom in a patient's bloodstream. Enables healthcare workers to quickly diagnose snakebite type and select appropriate antivenom treatment. Designed for point-of-care use in resource-limited settings.
- Multiplex Lateral Flow Assay A lateral flow assay that distinguishes Bothrops and Lachesis venoms within 15 minutes, offering rapid point-of-care snakebite diagnosis. Allows naked-eye or smartphone-assisted quantitative detection with limit of detection of 10-50 ng/mL in spiked plasma and urine, and 50-500 ng/mL in spiked sera.
- Paper-based Diagnostic Platform (Nanobody-based) State-of-the-art paper-based diagnostic platform utilizing newly discovered nanobodies for detection and quantification of natural toxins (venoms and poisons). Designed for low-cost, fast, and sensitive point-of-care diagnosis in resource-limited settings.
Quantifiable outcome
- Detects Bothrops and Lachesis venoms within 15 minutes at point of care
- +2 more outcomes
Companies that use VenomAid Diagnostics
Customer profileSegments3 records
Ideal customer profiles2 records
VenomAid Diagnostics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
VenomAid Diagnostics partnerships and signals
Strategic signalPartnerships
Six partnerships are on record, tiered core and minor.
- Abingdon HealthcoreContract development and manufacturing organization (CDMO) partnership facilitating accelerated development of affordable, rapid snakebite diagnostic. The partnership has facilitated rapid production of prototypes to support clinical studies, streamlining the path from development to clinical validation.
- LIFE FoundationcoreCo-development of 'FIGHT THE BITE' - a free educational science course for Danish high school students focused on snakebite envenoming and diagnosis. The course has been pre-booked by more than 130 classes, reaching 3,000+ students. VenomAid contributed expert knowledge and design of the course curriculum.
- DTU Bioengineering (Technical University of Denmark)coreResearch institution partnership through the Center for Antibody Technologies for snakebite envenoming, toxinology, antibody technology, and diagnostics collaboration. The founding team met through DTU's Tropical Pharmacology Lab.
- Global Access DXminorPartner in VenomAid's collaborative network for global health impact in snakebite diagnostics and awareness.
- Center for Antibody TechnologiescoreDTU Bioengineering research unit specializing in antibody technology, partnering with VenomAid for antibody development and diagnostics innovation.
- FMT-HVDminorCollaborating partner in VenomAid's network of partners and collaborators for advancing snakebite diagnostics.
Scale indicators7 records
Recent moves7 records
Expansion highlights6 records
VenomAid Diagnostics competitors and assessment
Company assessmentBroad incumbents
- Bio-Rad Laboratories: Large established diagnostics and life science tools company with significant immunoassay and rapid test capabilities. Comparable as a broad incumbent with overlapping lateral flow and clinical diagnostic product lines that could compete in snakebite or tropical disease diagnostics.
- Abbott (Diagnostics): Global diagnostics leader with a major rapid diagnostics portfolio (e.g., BinaxNOW-style lateral flow platforms). Comparable as a broad incumbent in rapid point-of-care diagnostics with the scale to enter neglected tropical disease testing if it chooses to.
- SD Biosensor: Global manufacturer of rapid diagnostic test kits including lateral flow assays for infectious disease. Comparable as an incumbent with established lateral flow manufacturing and distribution that could compete with VenomAid in tropical disease diagnostics.
Direct peers
- Abingdon Health: UK-based CDMO specializing in lateral flow assay development and manufacturing. Comparable to VenomAid both as a lateral flow diagnostics developer and as its core manufacturing partner; operates in the same regulatory and technology space for rapid point-of-care diagnostics.
- Mologic (Global Access Diagnostics): Developer of lateral flow and rapid diagnostic tests for global health applications including neglected tropical diseases. Directly comparable to VenomAid in affordable point-of-care diagnostics targeted at resource-limited settings.
Emerging players
- InBios International: US-based developer of immunodiagnostics for infectious and tropical diseases, including lateral flow assays. Comparable to VenomAid in its focus on rapid immunoassay-based diagnostics for diseases affecting resource-limited populations.
- CTK Biotech: Develops and manufactures rapid diagnostic tests for infectious and tropical diseases using lateral flow technology. Comparable to VenomAid in product format (immunochromatographic rapid tests) and target use case (point-of-care diagnosis in low-resource settings).
- Micronics (DNAe): Developer of molecular and rapid point-of-care diagnostic platforms. Comparable as an emerging player in novel rapid diagnostic technologies that could eventually overlap with VenomAid's point-of-care toxin detection niche.
Others
- FIND (Foundation for Innovative New Diagnostics): Global non-profit driving development and adoption of diagnostics for poverty-related diseases, including NTDs. Comparable as a key ecosystem player funding and shaping the market for snakebite and other NTD diagnostics that VenomAid targets.
- PATH: Global health non-profit with significant programs in NTD and tropical disease diagnostics development. Comparable as an ecosystem participant that influences funding, clinical trial infrastructure, and public-sector adoption pathways relevant to VenomAid's market entry.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks7 records
Key highlights6 records
Customer concentration
VenomAid Diagnostics social profiles
Digital presenceVenomAid Diagnostics financial estimates
Financial estimateRevenue estimate
Valuation estimate
VenomAid Diagnostics leadership team
Management profileNumber of profiles
Profiles14 records
VenomAid Diagnostics funding detail
Funding detailFunding overview
Funding rounds3 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
VenomAid Diagnostics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about VenomAid Diagnostics
What does VenomAid Diagnostics do?
VenomAid Diagnostics develops affordable, rapid in vitro diagnostic tests for snakebite envenoming using proprietary monoclonal antibody and nanobody-based lateral flow assay technology. The flagship Bothrops Kit uses a small patient blood sample to detect Bothrops genus snake venom at point of care within 15 minutes, enabling healthcare workers in resource-limited settings to quickly identify venom type and select appropriate antivenom treatment.
Is VenomAid Diagnostics a public or private company?
VenomAid Diagnostics is a private company. It is classified as venture growth investor backed and is currently operating.
When was VenomAid Diagnostics founded?
VenomAid Diagnostics was founded in 2018. It employs 1 to 10 people.
Where is VenomAid Diagnostics based?
VenomAid Diagnostics is headquartered in Kongens Lyngby, Denmark, in the Europe region.
How does VenomAid Diagnostics make money?
One revenue line is on record: bothrops Kit Sales.
Who are VenomAid Diagnostics's main competitors?
Broad incumbents on record are Bio-Rad Laboratories, Abbott (Diagnostics) and SD Biosensor. Direct peers are Abingdon Health and Mologic (Global Access Diagnostics). Emerging players are InBios International, CTK Biotech and Micronics (DNAe). Others are FIND (Foundation for Innovative New Diagnostics) and PATH.
Does VenomAid Diagnostics have an API?
No public API is recorded for VenomAid Diagnostics.
What industry is VenomAid Diagnostics in?
VenomAid Diagnostics's product category is In Vitro Diagnostics. Its primary akta.pro industry code is HLAHAOAG, Drug-of-Abuse & Toxicology Rapid Tests (Urine/saliva panels), with a secondary code of HLAAALAB, Immunoassay Diagnostics (ELISA, chemiluminescence, serology). Its NAICS code is 325413 and its SIC code is 2835.